# |
PMID |
Sentence |
1 |
26832955
|
Caspase-1, but Not Caspase-3, Promotes Diabetic Nephropathy.
|
2 |
26832955
|
Here, we administered two partially disjunct polycaspase inhibitors in 8-week-old diabetic (db/db) mice: M-920 (inhibiting caspase-1, -3, -4, -5, -6, -7, and -8) and CIX (inhibiting caspase-3, -6, -7, -8, and -10).
|
3 |
26832955
|
Accordingly, analysis of gene expression data in the Nephromine database revealed persistently elevated glomerular expression of inflammasome markers (NLRP3, CASP1, PYCARD, IL-18, IL-1β), but not of apoptosis markers (CASP3, CASP7, PARP1), in patients with and murine models of dNP.
|
4 |
26832955
|
In vitro, increased levels of markers of inflammasome activation (Nlrp3, caspase-1 cleavage) preceded those of markers of apoptosis activation (caspase-3 and -7, PARP1 cleavage) in glucose-stressed podocytes.
|
5 |
26832955
|
Finally, caspase-3 deficiency did not protect mice from dNP, whereas both homozygous and hemizygous caspase-1 deficiency did.
|
6 |
26832955
|
Hence, these results suggest caspase-3-dependent cell death has a negligible effect, whereas caspase-1-dependent inflammasome activation has a crucial function in the establishment of dNP.
|
7 |
32696822
|
MicroRNA-770-5p contributes to podocyte injury via targeting E2F3 in diabetic nephropathy.
|
8 |
32696822
|
MicroRNA-770-5p depletion could repress high glucose (HG)-triggered apoptosis in podocytes, and downregulation of E2F transcription factor 3 (E2F3) could facilitate podocyte injury.
|
9 |
32696822
|
Nevertheless, whether E2F3 is involved in miR-770-5p knockdown-mediated improvement of DN is still unclear.
|
10 |
32696822
|
The expression levels of miR-770-5p and E2F3 were detected in HG-treated podocytes by RT-qPCR.
|
11 |
32696822
|
The expression levels of E2F3, apoptosis-related proteins Bcl-2 related X protein (Bax), B-cell lymphoma-2 (Bcl-2), Bad, apoptotic peptidase activating factor 1 (APAF1), C-caspase3, C-caspase7, and C-caspase9 were detected by western blot assay.
|
12 |
32696822
|
The effects of miR-770-5p and E2F3 on HG-treated podocytes proliferation and apoptosis were detected by CCK-8 and flow cytometry assays.
|
13 |
32696822
|
The interaction between miR-770-5p and E2F3 was predicted by Targetscan, and then verified by the dual-luciferase reporter assay.
|
14 |
32696822
|
MiR-770-5p was upregulated and E2F3 was downregulated in HG-treated podocytes.
|
15 |
32696822
|
MiR-770-5p inhibited proliferation and promoted apoptosis and E2F3 promoted proliferation and suppressed apoptosis in HG-treated podocytes.
|
16 |
32696822
|
E2F3 is a target gene of miR-770-5p and it partially abolished the effect of miR-770-5p in HG-triggered proliferation and apoptosis of podocytes.
|
17 |
32696822
|
MiR-770-5p deficiency blocked HG-induced APAF1/caspase9 pathway via targeting E2F3 in podocytes.
|
18 |
32696822
|
We firstly confirmed that E2F3 was a target of miR-770-5p in podocytes.
|
19 |
32696822
|
These findings suggested that miR-770-5p expedited podocyte injury by targeting E2F3, and the miR-770-5p/E2F3 axis might represent a pathological mechanism of DN progression.
|